RISK FACTORS AND CLINICAL FEATURES OF COMORBID ATOPIC DERMATITIS IN CHILDREN
Abstract
Atopic dermatitis is a multifactorial disease caused by the combined effects of genetic changes and trigger mechanisms in the body. It is known that the etiopathogenetic "basis" of multifactorial diseases is the creation of a certain polymorphic form of functionally defective genes (genetic "predispositions", candidate genes, mediator genes) that have a detrimental effect on the environment. Based on historical sources, atopic dermatitis is an "abnormal" genetically determined reaction of the body to inhalation and food allergens, characterized by an increase in the amount of immunoglobulin E (IgE) and specific IgE antibodies in response. In our current work, we will consider the origin of atopic dermatitis and its relationship with other allergic diseases. Risk factors for comorbidity are identified. Materials and methods of the study. The study included 130 children aged 6 to 12 years with bronchial asthma and AtD, who underwent inpatient treatment at the multidisciplinary clinic of the Tashkent Medical Academy in 2019-2024. Study results. Medical, biological and social risk factors for the development of atopic dermatitis in comorbidity with bronchial asthma were identified; the significance of determining the amount of Cys-LT in urine for the early diagnosis of atopic dermatitis in comorbidity with bronchial asthma was established; a method for the early diagnosis of atopic dermatitis in comorbidity with bronchial asthma was developed, a treatment method was improved, the effectiveness of which is based on the determination of leukotrienes in urine and specific IgE in the blood. Conclusion. Based on the obtained scientific results on the identification of clinical manifestations of atopic dermatitis comorbid with bronchial asthma, improvement of diagnostic and treatment methods: optimization of treatment methods and their use at the primary stage in the comorbid course of atopic dermatitis with bronchial asthma in children.
About the Authors
List of references
Atopic dermatitis: clinical guidelines. - 2020. [Atopicheskii dermatit: Clinical guidelines.(InRuss).] Available at: https://nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf. The link is active on 09.24.2022.
Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–677.e7. doi: https://doi.org/ 10.1016/j.jaci.2015.03.051
Wollenberg A, Ehmann LM. Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema. Ann Dermatol. 2012;24(3):253.doi: https://doi.org/10.5021/ad.2012.24.3.253
Amat F, Soria A, Tallon P, et al. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: An overview. Clin Exp Allergy. 2018;48(8):919–934. doi: https://doi.org/10.1111/cea.13156
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: https://doi.org/10.1111/jdv.14891
Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350–358. doi: https://doi.org/10.1016/j.jaci.2016.06.002
Granato L. Modulator from fractions of vegetable unsaponifiables.Personal Care. 2012;09:69–72.
Mirraximova M. X. et al. Night of atopic dermatitis in children komorbid laboratory-immunological properties //IMRAS. – 2023. – Т. 6. – №. 6. – С. 301-306.
Kh M. M., Kurbanova D. R., Nishanbaeva N. Y. Identification of clinical and laboratory changes of the gastrointestinal tract in atopic dermatitis in children and improvement of the principles of diagnosis and treatment/ISSN 2181-712X.
Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march.Biochem Med (Zagreb). 2019;29(2):214–227. doi: https://doi.org/10.11613/bm.2019.0205
Man MQ, Barish GD, Schmuth M, et al. Deficiency of PPARbeta/ delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol. 2008;128(2):370–377. doi: https://doi.org/10.1038/ sj.jid.5701026
Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications. J Dermatol. 2014;41(3):205–212. doi: https://doi.org/10.1111/ 1346-8138.12317
Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in Atopic Dermatitis. Immunol Allergy Clin North Am. 2017;37(1):113–122. doi: https://doi.org/10.1016/j.iac.2016.08.007
Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792–799. doi: https://doi.org/10.1016/j.jaci.2014.06.014
Dale BA, Presland RB, Lewis SP, et al. Transient Expression of Epidermal Filaggrin in Cultured Cells Causes Collapse of Interme diate Filament Networks with Alteration of Cell Shape and Nuclear Integrity.J Invest Dermatol. 1997;108(2):179–187. doi: https://doi.org/ 10.1111/1523-1747.ep12334205
Stout TE, McFarland T, Mitchell JC, et al. Recombinant filaggrin is in - ternalized and processed to correct filaggrin deficiency. J Invest Der ma tol. 2014;134(2):423–429. doi: https://doi.org/10.1038/jid.2013.284
Kim JH, Bae HC, Ko NY, et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J Allergy Clin Immunol. 2015;136(1):205–208.e9. doi: https://doi.org/10.1016/j.jaci.2015.04.026
Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131(4):1094–1102. doi: https://doi.org/10.1016/j.jaci.2012.12.1566
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.